Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
about
Mechanism of action of lenalidomide in hematological malignanciesBiological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaCereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateLenalidomide and chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaImmunological aspects in chronic lymphocytic leukemia (CLL) developmentImpaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)How will B-cell-receptor-targeted therapies change future CLL therapy?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib'Trained immunity': consequences for lymphoid malignanciesLymphoma: immune evasion strategiesT cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatasesA novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Autoimmune cytopenias in chronic lymphocytic leukemia.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism.T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemiaSelective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelImmunologic aspects of monoclonal B-cell lymphocytosisToll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemiaLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease.
P2860
Q21198872-6C66F4D0-FF48-46E0-A174-3481BFFEC4AEQ21285161-7EF83F15-6688-4FFF-A7D4-6909CDD1E2F7Q24614147-944824DB-7D1C-41B1-812F-5134FBEF62A2Q24632975-5AA5C96D-1703-4AA2-B6AD-E7B1C8B82399Q26770391-C80486AD-54E0-4752-95D2-ABB083F1A84CQ26773053-8950CF73-104B-40EE-817F-589C3075B661Q26795540-C427685F-DFE4-487D-A8A9-6A93B24A4F5FQ26798062-128279EC-6BCD-4208-A1AA-1F5600F2694BQ26823597-E443BC13-B6A8-45BF-80A4-1D6844A8E698Q26865561-0EA28135-8797-495F-B904-CFE0E7A1E453Q26865940-591A85FA-C364-41F0-B702-CDB78A784D8FQ27003955-AA97AD43-E8C0-4F1D-A722-2E471DB33E47Q27004421-2C7151BD-D85C-41C1-B79B-32712939C2C6Q27024187-7B4FD8EB-660E-4209-906A-4BF73668358DQ27025812-2DA8E3FF-FECE-4197-AE13-EAA3D73FD3F2Q28074639-3EAC558F-3766-4D71-894D-3DE6DFCCCB03Q28080705-F72DDC2A-CA51-4B3D-9099-77FB49A025FDQ28510998-C8C43DA0-6BA4-4334-8748-74F4A0411E18Q30008755-97A8EABE-6210-427C-8A4F-374CE7B34026Q30538420-54C3B002-B26E-4628-90FF-1471578B677BQ33407866-8135E9D2-C3BA-42D1-ABD0-C487DB36AA50Q33436535-9F3EBF72-5425-4512-93AE-5075A88590E1Q33558697-B8BF40E6-AB6E-4AE1-8543-A1F45E854D03Q33573774-F6EE6FD2-8C6E-4BA9-B9AD-94F84A3ED639Q33621881-271B6D8F-D175-4A2A-955D-7C04E6DF1C1EQ33655756-2D6E5CAA-F31E-4ED1-AA01-2CA9F5E7B204Q33718767-5EE434FF-63C0-4825-9655-4F6A720AFF04Q33780253-FB007A3C-5BCE-4E56-A4F3-DDDE32B21DF2Q33796183-B0853C4A-20D7-475A-B236-B274D532211AQ33829089-C9DE3276-71E6-4C58-AFC2-57AA3F19E59DQ33875604-3B461F28-134E-4400-AD81-3C4BD067C404Q33915138-A0B9F858-EC53-4AEC-92DB-5CF5B6B78D8BQ33931707-1784A73E-DC2E-400F-AAB2-CEAE88CF1F94Q33965681-3596579D-F25E-4263-BCD2-84538AF07BD7Q34008584-B7B78DF8-E666-4E13-A8D9-3046894BC6FFQ34009041-6AE02A9B-5A0F-4213-98E1-AC9E9F1D54F0Q34137016-759C700D-3C45-4121-87E3-B9378B3C0D89Q34172063-85D79C2A-D017-47AB-8FCC-BE054C3E2FA2Q34278096-4CADC02E-0B6A-40CE-9D85-282132CF9300Q34294166-29712C95-980F-49E9-A732-BB701A5D7D31
P2860
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@ast
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@en
type
label
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@ast
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@en
prefLabel
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@ast
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@en
P2093
P2860
P356
P1476
Chronic lymphocytic leukemia T ...... with an immunomodulating drug.
@en
P2093
Abigail M Lee
Alan G Ramsay
Amy J Johnson
Güllü Gorgün
John G Gribben
Rifca Le Dieu
William Blum
P2860
P304
P356
10.1172/JCI35017
P407
P50
P577
2008-07-01T00:00:00Z